Mizoribine

Mizoribine (NSC 289637), an imidazole nucleoside, inhibits HCV RNA replication with IC50 of approximately 100 μM for anti-HCV activity. Immunosuppressant[1]. Mizoribine, an IMPDH inhibitor, inhibits replication of SARS-CoV with IC50s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively[2].

Product Specifications

CAS Number

[50924-49-7]

Product Name Alternative

NSC 289637; HE 69

UNSPSC

12352005

Hazard Statement

H315, H319, H335, H360

Target

Antibiotic; HCV; Parasite; SARS-CoV

Type

Natural Products

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Mizoribine.html

Purity

99.99

Solubility

DMSO : 62.5 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

Smiles

OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(O)=C(C(N)=O)N=C2)O1

Molecular Formula

C9H13N3O6

Molecular Weight

259.22

Precautions

H315, H319, H335, H360

References & Citations

[1]Naka K, et al. Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha. Biochem Biophys Res Commun. 2005 May 13;330 (3) :871-9.|[2]Saijo M, et al. Inhibitory effect of Mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS) -associated coronavirus. Antiviral Res. 2005 Jun;66 (2-3) :159-63.|[3]Kamada H, et al. Effect of Mizoribine on collagen-induced arthritis in mice. Jpn J Pharmacol. 1996 Feb;70 (2) :169-75.